Immunology of Periodontal Disease
On this page
Direct answer
Bacteria initiate periodontal disease; the host response executes the destruction. Neutrophils leave the vasculature within minutes of plaque antigenic challenge, and complement (C3b opsonising, C5a recruiting) amplifies their arrival; if innate clearance falters, the adaptive response layers on — T helper subsets assigning outcomes rather than merely reacting. The classical Th1/Th2 paradigm (Th1 cell-mediated stable lesions versus Th2 antibody-rich progressive lesions) has been overtaken by the Th17/Treg axis: interleukin-17 from Th17 cells recruits neutrophils and drives RANKL-mediated osteoclastogenesis, while regulatory T cells restrain damage through interleukin-10 and TGF-beta. The final common pathway of bone loss is the RANKL-RANK-OPG triad, and the soft-tissue destruction is matrix metalloproteinase work — MMP-8 above all, measurable in gingival crevicular fluid.
What you must remember
- Innate layer: neutrophils are first and indispensable — their defects (chemotaxis impairment, adhesion failure) define the aggressive periodontitis phenotypes of leukocyte adhesion deficiency, Chédiak-Higashi syndrome and cyclic neutropenia.
- Complement: alternative and classical pathways generate C3b (opsonisation) and C5a (neutrophil chemotaxis, anaphylatoxin); sustained activation feeds bone loss.
- T helper map: Th1 (interferon-gamma, macrophage activation) and Th17 (interleukin-17, neutrophil recruitment, RANKL expression) drive destructive inflammation; Th2 (interleukin-4, antibody) is humoral; Treg (interleukin-10, TGF-beta) resolves and contains.
- Bone resorption axis: RANKL (on Th17 cells, fibroblasts, osteoblasts) binds RANK on osteoclast precursors and drives differentiation; osteoprotegerin is the decoy receptor — the ratio of RANKL to OPG decides bone fate in periodontitis.
- Cytokine cascade: interleukin-1 beta and TNF-alpha are the dominant destructive mediators (inducing MMPs and PGE2, promoting osteoclasts), with interleukin-6 linking inflammation to bone and B-cell responses.
- Prostaglandin E2: rises in crevicular fluid with active disease and stimulates osteoclastic bone resorption — the classical biochemical marker of progression studies.
- Matrix metalloproteinases: MMP-8 (neutrophil collagenase) dominates gingival crevicular fluid, with MMP-9 and MMP-13 contributing; tissue inhibitors of metalloproteinases (TIMPs) counterbalance — the rationale for sub-antimicrobial dose doxycycline.
- Histological stages (Page and Schroeder): initial lesion (first days, neutrophil exudate), early lesion (within about a week, lymphocyte predominance), established lesion (two to three weeks, plasma cells), advanced lesion (bone loss — periodontitis).
Following the cascade from biofilm to bone
Trace one gram-negative challenge end to end. Lipopolysaccharide penetrates the porous junctional epithelium and binds Toll-like receptor 4 on macrophages and fibroblasts; interleukin-1 beta and TNF-alpha pour out; complement activates downstream of the bacterial proteases; neutrophils cross the wall in bulk, releasing MMP-8 as they work. Locally, Th17 cells arriving in the infiltrate produce interleukin-17, which does two things examiners want named: it recruits further neutrophils (amplifying the protease flood) and upregulates RANKL expression on fibroblasts and osteoblasts. RANKL engages RANK on osteoclast precursors, which fuse and activate — and the crest begins to resorb, with osteoprotegerin overwhelmed. Resolution is the same machinery in reverse: regulatory T cells and pro-resolving lipid mediators dial down interleukin-17, MMP activity falls to TIMP control, and the RANKL-to-OPG ratio tilts protective. Every drug target in periodontology — doxycycline on MMPs, non-steroidals on PGE2, host-modulation generally — is one node on this map.
Where students slip
The outdated paradigm is the trap: persisting with "Th1 stable, Th2 progressive" as current dogma earns correction, because the modern view centres Th17-driven inflammation and RANKL-mediated osteoclastogenesis, with Th2 biology retained mainly for antibody-dominant lesions. Second slip: naming osteoclasts as the source of RANKL — they are its target; RANKL comes from Th17 cells, fibroblasts and osteoblasts, and osteoprotegerin is the decoy that neutralises it. Third: crediting bacteria with direct collagenolysis — the host's MMP-8 does most of the collagen destruction, which is why a drug that inhibits collagenase (sub-antimicrobial doxycycline) can treat a bacterial disease's aftermath. Fourth, the histology sequence's timing — initial within days, early around a week, established at two to three weeks — is quoted as naked numbers in MCQs.
Frequently asked questions
Which T helper subset most directly drives periodontal bone loss?
Th17 cells, through interleukin-17 that recruits neutrophils and upregulates RANKL expression, promoting osteoclast differentiation.
How does the RANKL-RANK-OPG system control alveolar bone?
RANKL binding RANK on osteoclast precursors drives bone resorption; osteoprotegerin acts as a decoy receptor, and the RANKL-to-OPG ratio sets the balance.
Which enzyme is the predominant collagenase in gingival crevicular fluid?
MMP-8, the neutrophil collagenase — which host-modulation therapy with sub-antimicrobial dose doxycycline directly targets.
Which histological stage marks the transition from gingivitis to periodontitis?
The advanced lesion of Page and Schroeder, where plasma-cell-rich inflammation breaches bone — the earlier stages remain gingival.
Why do neutrophil disorders produce aggressive periodontitis?
Because first-line bacterial clearance fails, compensation escalates inflammation, and congenital defects (adhesion, chemotaxis, cycling) let commensal-level plaque destroy attachment rapidly.